22 results on '"Braun, Ada H."'
Search Results
2. Transmembrane and Soluble Isoforms of Heparin-Binding Epidermal Growth Factor–Like Growth Factor Regulate Distinct Processes in the Pancreas
3. Assessing Analgesic Use in Patients with Advanced Cancer: Development of a New Scale—The Analgesic Quantification Algorithm
4. Phase III trials in oncology: setting standards of care?
5. Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor
6. A randomized, double-blind, multinational trial comparing denosumab with zoledronic acid for treatment of bone disease in adults with newly diagnosed multiple myeloma
7. Durability and characteristics of objective tumor responses with the innate immune cell modulator Imprime PGG in combination with standard of care frontline treatment for patients (Pts) with metastatic non-squamous NSCLC.
8. A phase (Ph) 1/2 trial of rituximab (RX), imprime PGG (IP), and alemtuzumab (AL) in the early treatment of patients (Pts) with high risk chronic lymphocytic leukemia (CLL).
9. Safety of Imprime PGG, a novel innate immune cell modulator, in adults with stage IV non-small cell lung cancer: an integrated analysis of two randomized phase 2 studies.
10. A phase 3 open-label, randomized, multicenter study of imprime PGG in combination with cetuximab in patients with KRAS wild type metastatic colorectal cancer.
11. Phase Ib study of PGG beta glucan in combination with anti-MUC1 antibody (BTH1704) and gemcitabine for the treatment of advanced pancreatic cancer.
12. The evaluation of denosumab safety in patients with chronic kidney disease: An open-label study.
13. A randomized, double-blind, multinational trial comparing denosumab with zoledronic acid for treatment of bone disease in adults with newly diagnosed multiple myeloma.
14. Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal-related events (SREs) in patients with metastatic bone disease: Subgroup analyses by baseline characteristics.
15. A Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer
16. Denosumab For The Treatment Of Hypercalcemia Of Malignancy Refractory To IV Bisphosphonates In Patients With Hematologic Malignancies
17. Reply to Araki et al.
18. Incidence of osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases from solid tumors or multiple myeloma: Results from three phase III trials.
19. Health state preferences associated with subcutaneous injections and intravenous infusions for treatment of bone metastases.
20. Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase III clinical trial.
21. Lysophosphatidic Acid, a Disintegrin and Metalloprotease-17 and Heparin-Binding Epidermal Growth Factor–Like Growth Factor in Ovarian Cancer: The First Word, Not the Last
22. New systemic frontline treatment for metastatic colorectal carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.